|Bid||23.22 x 900|
|Ask||24.54 x 900|
|Day's Range||22.52 - 24.05|
|52 Week Range||10.10 - 24.77|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.20|
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming 39th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 13, 2020 at 5:20 p.m. Eastern Standard Time.
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Merilee Raines to its Board of Directors and as a member of the Audit Committee, effective January 1, 2021. The Board appointed Ms. Raines as Chair of the Audit Committee, effective as of June 1, 2021.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 817 world-class investment firms that we track and now have access to the collective wisdom contained in […]